Latest news with #IceCureMedical
Forbes
7 days ago
- Health
- Forbes
Peer Education: One Of The Most Underrated Growth Engines In Medtech
Tlalit Bussi Tel Tzure is the Vice President of Business Development and Global Marketing for the Medical Device Company, IceCure Medical. In medtech, where adoption of new technologies can be cautious and slow, one powerful driver that often goes overlooked is peer education. We've all experienced the power of a referral—when someone you trust recommends a book, a treatment or a restaurant, you're far more likely to give it a try. It's not about the pitch. It's about trust. In medicine, that same dynamic plays out every day. When physicians learn directly from their peers—not sales reps or marketing teams—it carries real weight. A simple, authentic statement like 'I've used this technology, and it really helped my patient' can open doors that no polished demo ever could. In this article, I will share my experience on why peer education works so well in medtech—and how, when done right, it can become a strategic engine for growth and lasting adoption. When Trust And Confidence Start With Peer Experience In healthcare, it makes perfect sense that doctors are cautious with new treatment options. These are decisions that deeply impact the health of patients, and no one takes that lightly. That's why it's so powerful when a physician can speak to someone who's already using the technology and come out the other side more confident. I remember clearly the first time I witnessed this in action: the power of one physician describing their experience with my company's cryoablation system to a colleague who was still on the fence. There was no fancy presentation. No pressure. Just a real, honest conversation rooted in clinical experience. That kind of exchange doesn't just build trust; it fosters real confidence. This is why peer education is more than just a helpful tool, but rather a growth engine that can open doors and create the kind of clinician-led adoption that drives long-term success. Why Peer Learning Works—Business Value, Not Just Clinical Comfort Doctors are not interested in being 'sold to' by companies. They want stories from the field from someone who has used the same tool in real-life situations and can speak authentically about patient outcomes. Peer education works because it bridges the gap between theory and practice and opens a dialogue. Sharing a lived experience delivers clinical credibility and emotional reassurance. It shortens the path to adoption and lowers the perceived risk of using a new technique. This is why I see peer-to-peer education as an extension of a company's go-to-market strategy. It's how companies can accelerate confidence, build adoption and, ultimately, support better care. Peer Learning Models That Work: Intimate, Strategic And High-Touch In medtech, the most effective peer education models are those that align closely with how physicians prefer to learn: through authentic, practical interactions with their peers. Rather than relying on sales-driven presentations, smaller hands-on sessions—often led by experienced users or key opinion leaders (KOLs)—create space for authentic clinical discussions. I have found these intimate, peer-led formats consistently foster deeper engagement and greater confidence in adopting new technologies and can do more to shift clinical perspective than months of traditional follow-up. Tailoring Peer Education To Different Prospect Types Not every physician learns the same way. Senior clinicians and KOLs often benefit most from direct, strategic dialogue with respected global peers. I've seen this in action: A leading breast surgeon from the United States and a radiologist from South Africa engaged with a highly regarded breast surgeon who is one of the pioneers of breast cancer cryoablation. The learning went far beyond technical instruction—it became a strategic conversation between peers shaping the future of care. But other surgeons and breast radiologists who are focused on broadening their treatment offerings may prefer accessible formats like hands-on workshops at events such as those held by the Society of Breast Imaging or the American Society of Breast Surgeons. Sessions like these can offer practical exposure and structured learning through a recognized association of experts in their medical specialty. Building The Right KOL Relationships—Years In The Making Building successful KOL relationships relies on trust built over the years. KOLs aren't just spokespeople; they are strategic collaborators, early product co-creators and long-term champions. The most impactful KOLs often: • Help shape device usage and treatment protocols. • Participate in investigator-led studies, case reports and webinars. • Provide critical feedback that informs product direction. Throughout my years in the medical device field, I've seen firsthand how building the right relationship with a KOL who is truly passionate about delivering the best patient care can turn them into an exceptional product advocate. Involving physicians in shaping your technology and empowering them to help educate the next generation of doctors is not only rewarding—it can become a powerful driver of your business model. As another example, an interventional radiologist from CHU de Nimes in France hosted several fellow radiologists from throughout Europe who were looking to expand their knowledge in treating a broader range of tumor types. Through case discussions and observation, he helped his fellow professionals to explore how to apply new tools more widely in their own clinical settings. Why Trust Is The Real Growth Strategy Peer education isn't just a marketing gimmick. It is a key business strategy that plays a central role in adoption, especially for high-consideration products that require trust, not just awareness. When it's done well, peer education delivers more than conversions. It leads to stronger relationships, richer feedback loops and long-term growth. It transforms passive users into active champions. When people believe in your product and your team, that belief spreads faster than any campaign ever could. Forbes Business Development Council is an invitation-only community for sales and biz dev executives. Do I qualify?
Yahoo
06-08-2025
- Business
- Yahoo
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
CAESAREA, Israel, Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2025 before the Nasdaq Stock Market opens on Wednesday, August 13, 2025. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, August 13, 2025, at 11:00 am EDTUS: 1-888-407-2553Israel/International: +972-3-918-0696A live webcast will be available at: recording of the webcast will be available at: About IceCure MedicalIceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: its expected announcement of financial and operational results as of and for the six months ended June 30, 2025 and hosting a conference call related to such results . Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo - View original content: SOURCE IceCure Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
06-08-2025
- Business
- Forbes
Resilient Leadership In Crisis: Navigating Wartime Challenges As A CEO
Eyal Shamir is the CEO of IceCure Medical, developer of cryoablation systems for the destruction of benign and cancerous tumors. The need for medical treatment is constant, and in times of war, the demand to provide healthcare is often greater. For a medical device company, that means delivering no matter what—arriving at the office after a night of taking shelter from missiles, holding meetings from home while your children don't have school or supporting employees who have been called for military duty. Beyond the physical fatigue, the emotional toll is very heavy, and yet the company must keep moving forward. For CEOs in wartime, how can we best lead our company and support the people who count on us? Personally, I believe the best way to navigate business challenges in wartime is to simply lead by example. As the CEO of IceCure Medical in Israel, for the past 600 days and counting, I have been leading our company through wartime, while also volunteering with the Israeli Traffic Police to help keep our citizens safe. I will share my lessons learned in resilient leadership during wartime and how my volunteer work keeps me grounded and motivated during a crisis. The Role Of Essential Businesses In Wartime As an essential business in wartime, we cannot stop. Our responsibility as a medical device company delivering cryoablation systems for cancer patients means we must continue regardless of geopolitical circumstances. That's why we must think several steps ahead. Our business model has always integrated robust contingency plans and proactive logistics to keep supply chains operational. Our sales teams and distributors are equipped with additional inventory to create strategic buffers. This ensures that even when routes are disrupted, care for cancer patients remains uninterrupted. Ensuring continuity of healthcare means preparation, adaptability and execution under pressure. Leading By Example As CEO, I believe in professional and personal contribution. For 15 years, I have volunteered with Israel's Traffic Police, initially responding to accidents and incidents involving impaired drivers. Over time, I have taken on a leadership role at the headquarters and am responsible for ensuring driver safety along a section of the northern coast of Israel. On October 7, 2023, I was called to duty to manage traffic so that first responders and military could respond swiftly to the atrocities that took place. Under missile fire from Iran, we maintain open roads for the ambulances of Magen David Adom and the Home Front Command responding to damaged areas. Balancing these duties is challenging but offers valuable insights. It drives me and informs my decisions with a deeper understanding of daily struggles. In crisis management, leadership is about presence, engagement and inspiring others through actions. Our teams observe how we lead in tough times. I strive not only to lead from behind a desk but also to stand alongside my team and community, contributing in whatever way I can. Motivation Amid Missiles: Helping Your Team Keep Going During wartime, people face immense physical and emotional challenges. Nights disrupted by sirens and days filled with fatigue and uncertainty can wear down even the most resilient among us. As leaders, compassion is crucial. We must be patient, recognize the emotional burdens our teams carry and find ways to bring stability. Setting small, clear goals can help restore focus and a sense of progress. In healthcare, it's vital to remind our teams that their work matters more than ever. Human resources plays a key role through emotional check-ins, honest conversations and genuine support. I personally message our team to let them know I'm here for them. It's about supporting the operations and aiding the people who keep things running. Our teams look to us for strength, empathy and clarity. That's why I lead with intention, guided by five leadership lessons that ground me during these times. My 5 Leadership Lessons For CEOs Navigating Crisis • Be decisive, but stay adaptable. Make the best decisions you can with the information you have been given, and be ready to adjust. Flexibility beats perfection every time. • Lead with people, not just plans. Your team's well-being comes first. Check in. Be human. A small gesture can mean the world to those in a crisis. • Communicate openly, even when it's hard. Tough times reveal true character. Staying transparent and acting with integrity builds trust and stability. People don't expect perfect answers; they want honesty. Keep your team informed, even if the update is: 'We're still figuring it out.' Knowing there's a plan forming is better than being left in the dark. • Focus on what truly matters and what's achievable. Prioritize essential work and key customers, yet be realistic in terms of the crisis. Set clear, attainable goals that help your team feel progress. • Let constraints spark creativity. Wartime forces us to think differently. New problems emerge, and old ways of working may no longer fit the moment. Encourage your team to suggest bold ideas or new ways of working. Innovation doesn't pause—I have found it accelerates. Leading With Resilience And Optimism We can't control the geopolitical situation, but we can control how we lead through it. For me, that means showing up, staying steady and keeping perspective. As a CEO, staying optimistic is a responsibility. Optimism helps people push through uncertainty, reconnect with purpose and believe in what is next. We don't lead companies; we lead people. And when we stay human, hopeful and grounded, leading by example, we help our teams and business keep moving forward. Forbes Business Development Council is an invitation-only community for sales and biz dev executives. Do I qualify?
Yahoo
28-06-2025
- Business
- Yahoo
IceCure Medical (NASDAQ:ICCM) shareholders have earned a 51% CAGR over the last five years
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at the IceCure Medical Ltd (NASDAQ:ICCM) share price. It's 677% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. It's even up 6.2% in the last week. But this might be partly because the broader market had a good week last week, gaining 3.4%. Anyone who held for that rewarding ride would probably be keen to talk about it. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because IceCure Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last half decade IceCure Medical's revenue has actually been trending down at about 0.9% per year. This is in stark contrast to the strong share price growth of 51%, compound, per year. There can be no doubt this kind of decoupling of revenue growth and share price growth is unusual to see in loss making companies. I think it's fair to say there is probably a fair bit of excitement in the price. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). If you are thinking of buying or selling IceCure Medical stock, you should check out this FREE detailed report on its balance sheet. We're pleased to report that IceCure Medical shareholders have received a total shareholder return of 36% over one year. However, that falls short of the 51% TSR per annum it has made for shareholders, each year, over five years. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 3 warning signs we've spotted with IceCure Medical . If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Israel/International: +972-3-918-0696A live webcast will be available at: A recording of the webcast will be available at: About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. IR Contact:Email: investors@ PolyviouPhone: 732-232-6914Todd KehrliPhone: 310-625-4462 Logo - View original content: SOURCE IceCure Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
